Keytruda Approved for Leading Form of Lung Cancer

FRIDAY, Oct. 2, 2015 — Keytruda (pembrolizumab) has been approved by the U.S. Food and Drug Administration to treat advanced cases of the most common type of lung malignancy, non-small cell lung cancer (NSCLC).
The drug is approved for people whose…
Source: Topamax